- Home
- Publications
- Publication Search
- Publication Details
Title
Critical Appraisal of Amyloid Lowering Agents in AD
Authors
Keywords
-
Journal
Current Neurology and Neuroscience Reports
Volume 21, Issue 8, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-10
DOI
10.1007/s11910-021-01125-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aducanumab and the FDA — where are we now?
- (2021) Howard Fillit et al. Nature Reviews Neurology
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
- (2020) Kenta Yoshida et al. Alzheimers Research & Therapy
- P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results
- (2020) T. Bittner et al. CLINICAL NEUROPHYSIOLOGY
- Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
- (2020) Heather Guthrie et al. JOURNAL OF ALZHEIMERS DISEASE
- Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease
- (2020) Samantha Budd Haeberlein et al. Alzheimers & Dementia
- A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
- (2019) Francesco Panza et al. Nature Reviews Neurology
- Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1-40 deposition underlies plaque polymorphism in progressing Alzheimer’s disease pathology
- (2019) Wojciech Michno et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- INTREPAD
- (2019) Pierre-François Meyer et al. NEUROLOGY
- Investigational BACE inhibitors for the treatment of Alzheimer’s disease
- (2019) Bruno P. Imbimbo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
- (2019) Gregory Klein et al. Alzheimers Research & Therapy
- Amyloid assembly and disassembly
- (2018) Edward Chuang et al. JOURNAL OF CELL SCIENCE
- The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death
- (2018) Sofia Söllvander et al. Journal of Neuroinflammation
- ABBY
- (2018) Jeffrey L. Cummings et al. NEUROLOGY
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
- (2018) Joseph W. Arndt et al. Scientific Reports
- Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis
- (2018) Can Zhang et al. Scientific Reports
- Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
- (2018) Judite R. M. Coimbra et al. Frontiers in Chemistry
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
- (2018) Stina Tucker et al. JOURNAL OF ALZHEIMERS DISEASE
- Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
- (2018) Stephen Salloway et al. Alzheimers Research & Therapy
- Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies
- (2017) Jun Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation
- (2017) Zhuohao He et al. NATURE MEDICINE
- Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies
- (2017) Juan Carlos Polanco et al. Nature Reviews Neurology
- SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
- (2016) Michael C. Irizarry et al. Alzheimers & Dementia
- Diabetes and Cognitive Impairment
- (2016) Lindsay A. Zilliox et al. Current Diabetes Reports
- Pharmacological Agents Targeting γ-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer’s Disease Patients: A Systematic Review and Meta-Analysis
- (2016) Ross Penninkilampi et al. JOURNAL OF ALZHEIMERS DISEASE
- Gamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
- (2016) Matthew G. Bursavich et al. JOURNAL OF MEDICINAL CHEMISTRY
- Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice
- (2016) Ksenia V. Kastanenka et al. JOURNAL OF NEUROSCIENCE
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
- (2016) Mark Ultsch et al. Scientific Reports
- Aβ43 is neurotoxic and primes aggregation of Aβ40 in vivo
- (2015) Sylvie Burnouf et al. ACTA NEUROPATHOLOGICA
- Targeting Prodromal Alzheimer Disease With Avagacestat
- (2015) Vladimir Coric et al. JAMA Neurology
- Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease
- (2014) Dietmar Rudolf Thal et al. ACTA NEUROPATHOLOGICA
- Specific aromatic foldamers potently inhibit spontaneous and seeded Aβ42 and Aβ43 fibril assembly
- (2014) Katelyn M. Seither et al. BIOCHEMICAL JOURNAL
- Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases
- (2014) Jing L Guo et al. NATURE MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amyloid-β and Tau
- (2014) George S. Bloom JAMA Neurology
- Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue
- (2013) Jun-Xia Lu et al. CELL
- Survival in dementia and predictors of mortality: a review
- (2013) Stephen Todd et al. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
- Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease
- (2013) Usman A Khan et al. NATURE NEUROSCIENCE
- Neuropathological Alterations in Alzheimer Disease
- (2013) A. Serrano-Pozo et al. Cold Spring Harbor Perspectives in Medicine
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
- (2012) Vladimir Coric et al. ARCHIVES OF NEUROLOGY
- An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
- (2012) O. Adolfsson et al. JOURNAL OF NEUROSCIENCE
- The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
- (2012) Iryna Benilova et al. NATURE NEUROSCIENCE
- Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions
- (2011) Heidi Olzscha et al. CELL
- The Alzheimer’s therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity
- (2011) Peter J. Crouch et al. JOURNAL OF NEUROCHEMISTRY
- Potent amyloidogenicity and pathogenicity of Aβ43
- (2011) Takashi Saito et al. NATURE NEUROSCIENCE
- Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's Disease
- (2011) Paul A. Adlard et al. PLoS One
- Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
- (2010) Kaj Blennow et al. Nature Reviews Neurology
- Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy
- (2009) Seth Love Frontiers in Bioscience-Landmark
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial
- (2009) Robert C. Green JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
- (2008) Lars Lannfelt et al. LANCET NEUROLOGY
- Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease
- (2008) Saravanan S. Karuppagounder et al. NEUROCHEMISTRY INTERNATIONAL
- Therapeutics for Alzheimer’s disease based on the metal hypothesis
- (2008) Ashley I. Bush et al. Neurotherapeutics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started